Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 11 | 2025 | 319 | 2.650 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 204 | 1.470 |
Why?
|
| Brachytherapy | 8 | 2025 | 127 | 1.440 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 3142 | 1.060 |
Why?
|
| Chemoradiotherapy | 5 | 2020 | 327 | 1.050 |
Why?
|
| Radiotherapy Dosage | 10 | 2025 | 482 | 0.850 |
Why?
|
| Radiation Injuries | 5 | 2021 | 164 | 0.790 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 19 | 0.650 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 228 | 0.640 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 22 | 0.640 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.630 |
Why?
|
| Safety | 1 | 2020 | 148 | 0.610 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 188 | 0.610 |
Why?
|
| Radiotherapy | 3 | 2016 | 328 | 0.570 |
Why?
|
| Radiometry | 2 | 2016 | 61 | 0.540 |
Why?
|
| Radiosurgery | 2 | 2021 | 311 | 0.530 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 72 | 0.460 |
Why?
|
| Female | 42 | 2025 | 49938 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 296 | 0.420 |
Why?
|
| Radiation Oncology | 3 | 2019 | 125 | 0.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 188 | 0.400 |
Why?
|
| Radiotherapy, Conformal | 4 | 2020 | 89 | 0.400 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1208 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1105 | 0.380 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 335 | 0.360 |
Why?
|
| Lymph Nodes | 2 | 2016 | 566 | 0.350 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 108 | 0.340 |
Why?
|
| Radiation Dosage | 3 | 2025 | 236 | 0.320 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 114 | 0.320 |
Why?
|
| Middle Aged | 26 | 2024 | 28255 | 0.320 |
Why?
|
| Humans | 45 | 2025 | 95971 | 0.310 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 2082 | 0.310 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 176 | 0.300 |
Why?
|
| Dietary Supplements | 1 | 2010 | 133 | 0.300 |
Why?
|
| Sexism | 2 | 2019 | 57 | 0.300 |
Why?
|
| Skin | 3 | 2024 | 605 | 0.300 |
Why?
|
| Aged | 22 | 2024 | 20877 | 0.290 |
Why?
|
| Biological Products | 1 | 2010 | 179 | 0.270 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 131 | 0.260 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 7205 | 0.260 |
Why?
|
| Adult | 20 | 2024 | 28637 | 0.250 |
Why?
|
| Bone and Bones | 1 | 2007 | 279 | 0.250 |
Why?
|
| Prostate | 1 | 2010 | 422 | 0.250 |
Why?
|
| Organs at Risk | 2 | 2016 | 48 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1795 | 0.230 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2024 | 31 | 0.220 |
Why?
|
| Cisplatin | 3 | 2018 | 611 | 0.220 |
Why?
|
| Nocebo Effect | 1 | 2024 | 3 | 0.220 |
Why?
|
| Mammography | 1 | 2007 | 475 | 0.220 |
Why?
|
| Radiation, Ionizing | 1 | 2024 | 124 | 0.220 |
Why?
|
| Drugs, Generic | 1 | 2024 | 21 | 0.210 |
Why?
|
| Dysbiosis | 1 | 2024 | 91 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 313 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 202 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2017 | 323 | 0.190 |
Why?
|
| Anxiety | 1 | 2024 | 339 | 0.180 |
Why?
|
| Heart | 3 | 2018 | 591 | 0.180 |
Why?
|
| Young Adult | 7 | 2024 | 7001 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 62 | 0.170 |
Why?
|
| Hysterectomy | 2 | 2020 | 168 | 0.170 |
Why?
|
| Rectum | 3 | 2016 | 151 | 0.170 |
Why?
|
| Standard of Care | 1 | 2021 | 70 | 0.170 |
Why?
|
| Treatment Outcome | 10 | 2019 | 9092 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2641 | 0.160 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.160 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.160 |
Why?
|
| Depression | 1 | 2024 | 560 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 59 | 0.160 |
Why?
|
| Oximetry | 1 | 2020 | 90 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1173 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 115 | 0.150 |
Why?
|
| Microbiota | 1 | 2024 | 426 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2755 | 0.150 |
Why?
|
| Breast | 2 | 2011 | 296 | 0.150 |
Why?
|
| Dilatation | 1 | 2019 | 48 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2025 | 10190 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 372 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 514 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 219 | 0.150 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.150 |
Why?
|
| Physicians, Women | 1 | 2019 | 61 | 0.150 |
Why?
|
| Postoperative Care | 2 | 2017 | 239 | 0.140 |
Why?
|
| Breath Holding | 1 | 2018 | 26 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 69 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 353 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 33 | 0.140 |
Why?
|
| Vagina | 1 | 2019 | 181 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 301 | 0.140 |
Why?
|
| Thoracic Wall | 2 | 2014 | 26 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2018 | 215 | 0.130 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 7 | 0.130 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 23 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 156 | 0.130 |
Why?
|
| Urinary Bladder | 2 | 2016 | 263 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2016 | 28 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2020 | 447 | 0.130 |
Why?
|
| Hydroxyurea | 1 | 2016 | 239 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 92 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 90 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 944 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2464 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2016 | 161 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 649 | 0.120 |
Why?
|
| Lung | 2 | 2014 | 1382 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 403 | 0.110 |
Why?
|
| Contrast Media | 1 | 2020 | 1095 | 0.110 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oxygen | 1 | 2020 | 787 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 79 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1765 | 0.110 |
Why?
|
| United States | 5 | 2021 | 7762 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1461 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2021 | 1006 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1269 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 64 | 0.110 |
Why?
|
| Male | 13 | 2024 | 45735 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 303 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1194 | 0.100 |
Why?
|
| Equipment Design | 1 | 2014 | 427 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 312 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 395 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 170 | 0.100 |
Why?
|
| Surgical Instruments | 2 | 2014 | 64 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 107 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 684 | 0.090 |
Why?
|
| Trigeminal Neuralgia | 1 | 2011 | 8 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1096 | 0.090 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 16 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 41 | 0.080 |
Why?
|
| Fatigue | 2 | 2024 | 185 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 880 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 178 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 161 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1007 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 619 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 844 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 285 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 5577 | 0.070 |
Why?
|
| Obesity | 2 | 2014 | 1038 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 166 | 0.060 |
Why?
|
| Adolescent | 4 | 2024 | 9888 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 711 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 159 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2533 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2876 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3635 | 0.060 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2024 | 1 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2024 | 35 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 82 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 259 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1760 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2785 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 174 | 0.050 |
Why?
|
| Mastectomy | 2 | 2016 | 270 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 100 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2014 | 4663 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1536 | 0.050 |
Why?
|
| Respiration | 2 | 2018 | 281 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2016 | 819 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1981 | 0.040 |
Why?
|
| Child | 3 | 2024 | 7624 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 517 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 61 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 228 | 0.040 |
Why?
|
| Attention | 1 | 2024 | 413 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 8 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1963 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 25 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 625 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 817 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 83 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 69 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 78 | 0.040 |
Why?
|
| Vincristine | 1 | 2018 | 112 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1978 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 259 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 311 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2018 | 303 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2019 | 206 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1562 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5949 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 98 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 397 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3901 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 94 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 179 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 386 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 125 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 3977 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 871 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1794 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1504 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1173 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 379 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 210 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 100 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1705 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 599 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 219 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2040 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1121 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 375 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 331 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 555 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1957 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1817 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1933 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 50 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 17 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 84 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 324 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 900 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2007 | 460 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2420 | 0.010 |
Why?
|